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Introduction
Cystic fibrosis (CF) is an autosomal recessive disease 
causing mutational defects of the CF transmembrane 
conductance regulator (CFTR) protein leading to multi 
organ involvement such as bronchiectasis, chronic sinusitis, 
pancreatic insufficiency, hepatobiliary disease, CF related 
diabetes, and osteoporosis. This gene is located on the long 
arm of chromosome 7. The median predicted survival of 
CF patients is 41.6 years based on the CF patient registry 
in 2015 (1). The mutation in the CFTR protein causes 
dysregulation of the chloride movement through the 
channel resulting in the production of thick, viscous mucus 
in the regions with the most CFTR expression (2). This 
buildup of thick mucus causes obstruction and inflammation 
leading to defective mucociliary clearance, chronic infection, 
and eventually organ failure (3).
Progressive respiratory disease remains the leading cause 
of morbidity and mortality in CF (2). The vicious cycle of 
mucus plugging, vigorous neutrophilic inflammation with 
the release of interleukin (IL)-8 neutrophil elastase have 
led to bronchiectasis by causing destruction of the airway 
tissue (4). With the profound neutrophilic inflammation, 
there is a release of deoxyribonucleic acid (DNA) that is 
broken down in the infected mucus increasing the viscosity 
of the secretions (5). Over time with small and medium 
airway obstruction and recurrent infections, the lung 
parenchyma undergoes atelectasis, collapse and pneumonia. 
The bronchial arterial circulation undergoes dilatation and 
neovascularity likely due to vascular endothelial growth 
factors in response to inflammation along with anastomotic 
changes at the capillary level (6). Several studies have 
looked into the various microbiological communities in 
CF with particular focus on certain organisms that are 
pathognomonic for CF such as Haemophilus influenza, 
Staphylococcus aureus, Pseudomonas aeruginosa, and 
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Burkholderia cepacia complex (7).
CFTR dysfunction is based on the mutations initiating at 
the level of protein translation with the loss or incomplete 
protein expression to conducting defects. The mutations are 
classified from I to V. Table 1 depicts the type of mutation 
and examples of mutations in the specific class. Some 
mutations may have features of more than one class. By 
understanding the different types of mutations, this helps 
to understand the disease presentation and design newer 
therapies specific for each mutation class (2).
Management of CF lung disease includes airway 
clearance with beta agonist bronchodilators, mucolytic 
agents such as inhaled dornase alpha and hypertonic saline, 
inhaled antibiotics such as tobramycin, aztreonam, and 
colistimethate in combination with chest physiotherapy 
and other percussive and osci l latory devices  (3) . 
CFTR modulators improve the function of the dysfunctional 
CFTR protein based on the mutation. Two such drugs that 
are used are Ivacaftor specific for gating mutations such 
as G551D mutation and defect in chloride conductance 
R117H and Lumacaftor-Ivacaftor for homozygous 
F508del mutation which is involved with CFTR protein 
trafficking and folding and channel gating. Studies have 
shown improvement in lung function and quality of life (3).
Microbiome in CF
The microbiology in the CF lung has a distinctive presentation 
over a period of time. Most often in the younger population, 
Staphylococcus aureus and Haemophilus influenza 
(nontypeable) followed by Pseudomonas aeruginosa. 
Different strains of Pseudomonas aeruginosa have been 
identified in several regions of the respiratory system (8,9). 
Other pathogens that are seen in the advance stage of CF 
include Burkholderia cepacia complex, Stenotrophomonas 
maltophilia, and fungi such as Aspergillus fumigatus 
and Scedosporium apiospermum. Non-tuberculous 
mycobacteria (NTM) are increasingly prevalent in CF 
with the most frequently identified species include 
Mycobacterium avium complex and Mycobacterium 
abscessus (10). 
Sputum cultures obtained quarterly from CF patients may 
not reveal the extensive microbiota in the airway as there 
are regional differences and diversity of the microbiota. 
However sputum cultures remain useful in monitoring 
most of the pathogens in connection with exacerbations (7). 
It has been established that the microbiome diversity 
decreases in advanced lung disease and in older CF patients 
whereas the microbiome in the younger CF patients have a 
higher diversity. This is likely due to use of antibiotics due 
to recurrent pulmonary exacerbations and the progressive 
decline in FEV1. It has also been suggested that pulmonary 
exacerbations may be due to spread of infection from other 
areas of affected airways to the unaffected airways instead of 
increased burden of the microbiome.
The microbiome identified in the lower airways is distinct 
from upper airway microbiome (11). Studies have shown 
various stages of disease in different regions of CF lungs 
as well as several pathogens distributed disproportionately 
throughout the lung (11,12). Combination of culture 
based studies and culture independent molecular studies 
have shown increased diversity and increased prevalence 
of anaerobic bacteria. With the increasing identification of 
uncommon bacteria, its relation to pulmonary exacerbations 
and decline in FEV1 still remains in question.
Table 2 demonstrates the most common pathogens seen in CF.
Utility of bronchoscopy in diagnosis and culture 
guided therapy in CF
Studies have shown sputum obtained from stable non CF 
bronchiectasis individuals may be useful as inexpensive and 
Table 1 CFTR class mutations
Class Defect Example
Class I Defect in protein expression causing premature stop mutation Nonsense mutations G542X
Class II Defect in processing and maturation delF508 (most common)
Class III Defect in regulation causing problems in activation and gating G551D
Class IV Defect in chloride conductance though the channel is activated R117H, R347P
Class V Decrease in amount of functioning protein 3849 + 10 kb C →T
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least invasive method to evaluate airway colonization of 
pathogens. However, not all individuals with bronchiectasis 
demonstrate the pathogenic microbiota in the lower 
airways with standard sputum collection. Induced sputum 
has been shown a preferred technique in evaluating airway 
colonization of pathogens (13).
In CF, expectorated sputum is useful for identifying 
pathogens for the management of pulmonary disease 
especially in individuals who are able to expectorate. In 
those who are not able to expectorate or have mild disease, 
sputum induction with nebulized 3 percent saline has been 
effective in measuring the inflammatory state which is 
comparable to expectorated samples (14). Bronchoalveolar 
lavage (BAL) cultures has been shown as a reliable 
method for in evaluating CF pathogens in comparison to 
nasopharyngeal cultures as well as identifying anaerobes in 
the younger population as compared to older population 
who have a less diverse microbiota (15-17).
Several studies have shown BAL culture from the most 
damaged lobe represented all the organisms as seen in 
the rest of the lung and that there is increased diversity 
in protected brush sampling as compared to BAL (16,17). 
Sputum cultures have been beneficial in identifying 
numerous bacteria but it does not reflect the entire diversity 
of the microbiome in the lower airways as compared to 
samples obtained by BAL or protected brush sample (15). 
With the increasing identification of diversity and bacterial 
burden noted on molecular based studies, there seems to be no 
increased bacterial burden in pulmonary exacerbations (17).
Henig et al. had looked at the airways of adult CF patients 
by sampling sputum induction using hypertonic saline, 
expectorated sputum and BAL with fiberoptic bronchoscope. 
The results showed that samples obtained by sputum 
induction had advantages including less quantity of squamous 
cells, marginally better microbiological results compared 
to BAL specimens, and similar quantities of inflammatory 
mediators. Each sampling techniques revealed similar 
characteristics that was predominant in the airways (18). 
Early identification of organisms, especially Pseudomonas 
aeruginosa, is important in the early eradication of 
Pseudomonas aeruginosa to prevent chronic infections 
and to identify other lower respiratory organisms to 
target appropriate antibiotics which is not easily identified 
with oral pharyngeal swabs and in those who cannot 
expectorate. Aaron et al. had looked at the presence of 
biofilm-forming Pseudomonas aeruginosa and whether 
the strains differ between sputum collection or protected 
brush specimens and BAL using fiberoptic bronchoscopy. 
Both BAL and protected brushings were not superior to 
sputum specimens for identifying the different strains 
of Pseudomonas aeruginosa and the differences in the 
antibiotic susceptibility. It was also shown that the sputum 
samples showed a better representation of the Pseudomonas 
aeruginosa strains since the sputum samples represented not 
only from distal airways from the upper airways as well as 
compared to BAL samples (19). 
Jain et al. reviewed that there was no benefit in 
bronchoscopy guided therapy compared to standard therapy 
which included sputum, throat swab, and cough swab on 
FEV1 and FVC and BMI in children. There were also 
increased hospital admissions in the BAL directed treatment 
but with shorter duration of stay. However, there was no 
significant reduction in the health care cost between the two 
groups (20). Wainwright et al. have shown that BAL directed 
therapy provided no benefit in regards to preventing 
structural changes on radiological imaging or reducing 
Pseudomonas aeruginosa infection in children. However, 
there were adverse events related to bronchoscopy with 
BAL which included clinical deterioration within 24 hours 
of BAL (4.8%), readmission post procedure (2.3%), 
contaminated bronchoscope (0.4%), fever greater than 
38.5 degree Celsius (7.6%), and transient worsening of 
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cough post procedure (29%) (20).
NTM are increasingly prevalent in CF as the CF 
population continues to age with the fact that there is an 
increase in organism load with advancing age. Studies 
have shown patients with non-tuberculous mycobacteria 
were older, have mild pulmonary disease, and often with 
Staphylococcus aureus in the sputum cultures (21-23). 
Isolating NTM is a challenge and often question whether the 
presence of NTM pose as a colonizer or cause for infection 
in the lungs (24). The combination of clinical evidence, 
radiological findings, and positive cultures including 
sputum and bronchial washings with non-tuberculous 
mycobacteria is essential for the diagnosis of non-tuberculous 
mycobacterial lung disease but it becomes a challenge in CF 
where identical symptoms have been associated with other 
pathogens (10,25). Tomashefski et al. had looked at the 
autopsies of CF patients who had positive sputum cultures 
for non-tuberculous mycobacteria and demonstrated 
only a small portion of patients with histological evidence 
of the disease (26). Tanaka et al. had demonstrated 
combination of computed tomography findings suggestive 
of Mycobacterium avium complex (MAC) along with 
positive bronchial washings for MAC and biopsies 
revealing granulomas indicated invasive disease rather than 
colonization in non CF patients (27). It is recommended 
that in CF patients who have positive cultures for NTM 
with clinical deterioration including pulmonary function 
and have excluded other conditions should be evaluated 
for NTM treatment (28-31). Bronchoscopy with BAL and 
transbronchial biopsies can be considered if there is a strong 
indication for evaluating and treating NTM.
Role of bronchoscopy in noninfectious causes in 
CF
Although there were studies to show the usefulness 
of bronchoscopy with endobronchial biopsies help to 
understand airway remodeling and to decelerate the 
progressive airway damage in children, hemoptysis has been 
noted more frequently in older CF patients with progressive 
lung disease associated with Pseudomonas aeruginosa, 
Burkholderia cepacia, and Staphylococcus aureus along with 
persistent airway inflammation and angiogenesis of bronchial 
arteries which are bordering to the airways (32-34). 
Endobronchial biopsies have been useful in understanding 
airway remodeling and inflammatory changes in early CF 
disease including in those who are asymptomatic (33). 
Despite the detailed understanding of airway remodeling, 
sampling has been limited to mostly in the proximal larger 
airways, smaller areas sampled, and lesser thickness of the 
airways as supposed to full thickness of the airways (34). 
Airway inflammation has been demonstrated in infants 
especially in those with negative cultures for the common 
bacterial and viral pathogens. Other changes noted include 
increase in airway smooth muscle cells which could play 
a role in airway hyper-responsiveness and destruction 
with fibrotic changes to cartilage which can lead to 
tracheomalacia and bronchomalacia seen in advanced 
CF disease (34-38). Reticular basement membrane 
thickening which has been demonstrated as part of airway 
remodeling in CF safe guards the airways by limiting 
proteolytic enzymes released from neutrophilic infiltration 
to the subepithelial space thus slowing down airway 
narrowing. As the disease progresses, the reticular basement 
membranes start to thin causing further inflammation of the 
airways (33). Vascular changes causing increased blood flow 
has been seen which is thought to be related to endothelial 
dysfunction potentiating vasoconstrictor pathways (34,39).
Lobar atelectasis has been reported up to 11% of 
CF patients (40,41). This is due various factors such 
as progression of disease, allergic bronchopulmonary 
aspergillosis, factors that would further alter the viscosity 
of sputum such as hyperglycemia and hemoptysis. 
Bronchoscopy with instillation of recombinant human 
DNase as single or sequential therapies have been 
reported after failure of standard of treatment including 
intravenous antibiotics, intermittent positive pressure 
breathing, and airway clearance therapy (42-46). Figure 1 
shows a computed tomography image of patient with CF 
demonstrating progressive right lung atelectasis.
Plastic bronchitis has also been reported in CF. Though 
it is rare, this is caused by acellular bronchial mucus casts 
made with mucin. One of the possibilities that cause 
plastic bronchitis is lymphatic drainage into the bronchus. 
Mechanical removal may be required with foreign body 
forceps (47,48). 
Tracheomalacia has been associated in children with CF 
especially in severe disease. The prevalence in children with 
CF is about 15% as compared to 1:2,100 rate estimated 
in the general pediatric population. It is more common in 
adults with CF with prevalence of 69%. Some of the factors 
that have been associated with tracheomalacia include 
(I) severe CFTR function leading to severe reduction in 
FEV1 developing secondary tracheomalacia due to airway 
infection, (II) abnormalities of the tracheal development 
predisposing to collapse, (III) combination of congenital 
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tracheomalacia with airway obstruction and infection. 
Apart from spirometry and computed tomography of 
the chest, flexible bronchoscopy is done to evaluate for 
dynamic airway collapse. Positive pressure ventilation can 
help improve respiratory symptoms by splinting open the 
airways. Pseudomonas aeruginosa has been linked with 
early and recurrent infections in children with CF and 
tracheomalacia. Other medical therapies that have been 
used include mucolytic therapy and Huff-cough. Placement 
of biodegradable airway stent to manage localized segments 
of tracheomalacia has been done (38,49-51).
Bronchoscopy is used for several reasons in CF most 
often for cultures directed for therapy but is used less 
often in the advent of similar microbiota seen in induced 
sputum. BAL has been considered ideal in obtaining 
cultures especially in those who are unable to expectorate. 
Now with routine monitoring of surveillance cultures done 
as outpatient in CF centers and analyzing the microbiota 
of the CF patients including the use of molecular 
studies, BAL cultures and protect brush sampling is 
almost as equivalent to sputum induction with better 
tolerance and less adverse events in sputum induction. 
Bronchial washings and transbronchial biopsies are still 
considered in evaluating NTM disease if there is a strong 
indication. There is utility in performing bronchoscopy 
for noninfectious reasons such as lobar collapse and 
tracheomalacia as this may be underdiagnosed due to the 
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